Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ruxolitinib cream in Chinese patients with atopic dermatitis
CTR20241697Phase 3Completed
- Sponsor
- Incyte
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Ruxolitinib cream with Placebo cream (2 arms). Primary endpoint: Proportion of participants achieving IGA treatment success. Started May 2024; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241697.